New England Journal of Medicine2021Open AccessHighly Cited

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

Juan P. Frías, Melanie J. Davies, Julio Rosenstock et al.

1,754 citations2021Open Access — see publisher for license terms1 related compound

Research Article — Peer-Reviewed Source

Original research published by Frías et al. in New England Journal of Medicine. Redistributed under Open Access — see publisher for license terms. MedTech Research Group provides these references for informational purposes. We do not conduct original research. All studies are the work of their respective authors and institutions.

Abstract

In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks. (Funded by Eli Lilly; SURPASS-2 ClinicalTrials.gov number, NCT03987919.).

Full Text

Full text is available at the publisher.

Read at Publisher
Article Details
DOI10.1056/nejmoa2107519
JournalNew England Journal of Medicine
Year2021
AuthorsJuan P. Frías, Melanie J. Davies, Julio Rosenstock, Federico C. Pérez Manghi, Laura Fernández Landó, Brandon K. Bergman, Bing Liu, Xuewei Cui, Katelyn Brown
LicenseOpen Access — see publisher for license terms
Citations1,754